upper
lower
respiratori
tract
infect
among
common
infecti
process
among
solid
organ
hematopoiet
stem
cell
transplant
hsct
recipi
infecti
syndrom
outlin
text
increas
risk
respiratori
tract
diseas
encount
transplant
recipi
relat
part
defect
innat
adapt
immun
within
popul
howev
incid
microbiolog
etiolog
respiratori
infect
quit
variabl
due
part
use
heterogen
immunosuppress
regimen
differ
prophylact
antibiot
strategi
addit
diminish
host
immun
anatom
breach
upper
lower
respiratori
tract
defens
may
increas
suscept
immunocompromis
host
varieti
common
opportunist
pathogen
anatom
consider
especi
import
patient
undergon
thorac
surgeri
lung
heart
transplant
individu
requir
prolong
mechan
ventil
medic
devic
nasogastr
endotrach
tube
hinder
coordin
glottic
movement
mucociliari
function
act
conduit
introduct
pathogen
organ
respiratori
tract
sever
immun
deficit
affect
transplant
recipi
consequ
increas
risk
upper
lower
respiratori
tract
infect
includ
commonli
associ
medic
toxic
chemotherapi
hematolog
malign
viral
infect
deficit
neutrophil
count
function
increas
risk
infect
staphylococci
streptococci
gramneg
bacilli
gnb
fungi
caus
mani
transplant
immunosuppress
medic
includ
calcineurin
inhibitor
mtor
inhibitor
glucocorticoid
lymphocyt
defici
also
encount
set
hiv
infect
lymphoma
leukemia
infectionreactiv
variou
herpesvirus
especi
cytomegaloviru
cmv
patient
cellular
immun
dysfunct
increas
risk
respiratori
infect
due
intracellular
organ
listeria
monocytogen
salmonella
spp
legionella
spp
toxoplasma
gondii
mycobacteria
fungilik
cryptococcu
spp
histoplasma
capsulatum
pneumocysti
jirovecii
well
cmv
human
herpesviru
varicellazost
viru
vzv
respiratori
virus
associ
variou
transplantoncolog
medic
like
azathioprin
mycophenol
rituximab
glucocorticoid
hematolog
malign
leukemia
multipl
myeloma
caus
humor
immun
defect
increas
risk
infect
encapsul
bacteria
includ
pneumonia
h
influenza
n
meningitidi
similarli
increas
risk
infect
encapsul
bacteria
well
capnocytophaga
immun
defect
often
mix
care
attent
clinic
radiograph
featur
well
recognit
nosocomi
versu
commun
sourc
infect
critic
make
correct
diagnosi
initi
empir
antimicrobi
therapi
solid
organ
transplant
hsct
recipi
delay
appropri
antimicrobi
therapi
may
increas
risk
secondari
complic
infectionassoci
death
especi
sever
immunosuppress
therefor
common
practic
initi
empir
preemptiv
antimicrobi
therapi
patient
suspicion
infect
high
chapter
review
common
respiratori
tract
infect
affect
transplant
recipi
includ
sinus
bronchiti
tracheobronch
pneumonia
particular
attent
direct
epidemiolog
risk
factor
includ
healthcar
exposur
clinic
present
diagnosi
common
microbiolog
etiolog
uniqu
caus
opportunist
pneumonia
review
final
section
chapter
sinu
infect
common
occurr
transplant
recipi
affect
hsct
recipi
probabl
similar
percent
solid
organ
transplant
recipi
note
transplant
patient
underli
cystic
fibrosi
cf
extrem
high
risk
sinus
individu
cf
show
pansinus
imag
month
age
hsct
recipi
risk
factor
develop
sever
rhinosinus
includ
graftversushost
diseas
gvhd
determin
sinus
solid
organ
transplant
recipi
less
clearli
defin
possibl
due
heterogen
diseas
process
prompt
transplant
unlik
nonimmunosuppress
individu
studi
link
tobacco
allergi
asthma
low
igg
level
sinus
transplant
recipi
gener
sinus
classifi
tempor
acut
week
subacut
week
chronic
week
term
sever
invas
noninvas
typic
sign
symptom
includ
nasal
congest
focal
sinu
pressur
pain
nasal
discharg
reduc
sens
smell
although
gener
case
transplant
recipi
often
mute
clinic
pictur
among
hsct
recipi
nasal
congest
cough
common
symptom
acut
sinus
respect
nonspecif
natur
symptom
may
ultim
lead
delay
diagnosi
result
poorer
clinic
outcom
invas
infect
diagnosi
acut
sinus
often
base
entir
clinic
present
immunocompet
patient
wherea
transplant
recipi
high
degre
suspis
due
dampen
clinic
sign
symptom
accompani
appropri
diagnost
investig
often
includ
ct
mri
scan
face
paranas
sinus
case
cultur
nasal
discharg
help
nasal
wash
bacteri
cultur
pcr
panel
assess
number
common
uncommon
respiratori
virus
may
consider
improv
diagnost
yeild
imag
obtain
fluid
level
found
case
although
wide
varieti
organ
caus
acut
sinus
vast
major
infect
due
viral
pathogen
includ
rhinoviru
respiratori
syncyti
viru
rsv
adenoviru
coronaviru
influenza
parainfluenza
even
cmv
viral
infect
shortliv
viral
shed
prolong
among
immunocompromis
patient
bacteri
sinu
infect
much
less
common
rare
occur
less
day
symptom
common
bacteri
caus
acut
bacteri
sinus
includ
pneumonia
haemophilu
influenza
moraxella
catarrhali
aureu
anaerob
pseudomona
promin
sinu
pathogen
cystic
fibrosi
patient
lung
transplant
case
acut
bacteri
sinus
caus
one
predomin
organ
one
quarter
two
distinct
pathogen
present
high
concentr
import
note
howev
routin
clinic
practic
major
patient
acut
sinus
bacteri
pathogen
isol
immunocompet
patient
treatment
acut
sinus
usual
support
except
case
symptom
persist
greater
day
point
empir
antimicrobi
therapi
may
warrant
sever
immunocompormis
transplant
patient
without
neutropenia
approach
start
treatment
earli
bacteri
sinu
infect
suspect
complic
acut
sinus
includ
facial
cellul
presept
periorbit
cellul
brain
abscess
cavern
sinu
thrombosi
orbit
invas
may
result
sight
life
threaten
orbit
postsept
cellul
intracran
extens
suspect
mental
statu
chang
occur
focal
neurolog
sign
ct
imag
mri
scan
urgent
obtain
otolaryngolog
evalu
endoscopi
sought
diagnosi
cultur
histolog
therapeut
drainag
empir
antimicrobi
initi
diagnost
evalu
pend
lung
transplant
recipi
underli
cystic
fibrosi
sinu
surgeri
decreas
recurr
pseudomonasrel
sinu
infect
invas
fungal
sinu
infect
associ
increas
morbid
mortal
may
rang
may
beupto
high
patient
undergo
solid
organ
allograft
allogen
hematopoiet
stem
cell
transplant
boni
eros
sign
invas
diseas
correl
chronic
invas
invas
sinu
diseas
often
fungal
although
bacteri
caus
pseudomona
aureu
uncommon
transplant
recipi
candida
aspergillu
speci
remain
common
fungal
organ
caus
sinus
result
invas
noninvas
sinu
diseas
rhizopu
also
import
organ
associ
rapidli
progress
infect
high
mortal
rate
even
rarer
fungal
etiolog
includ
scopulariopsi
fusarium
trichoderma
scedosporium
pseudallescheria
acanthamoeba
rare
welldescrib
parasit
caus
invas
rhinosinus
immunosuppress
patient
strong
predilect
intracran
involv
patient
brain
infect
carri
high
fatal
term
tracheobronch
acut
bronchiti
frequent
use
interchang
acut
bronchiti
preferenti
use
literatur
except
aspergillosi
ventilatorassoci
tracheobronchi
infect
gener
defin
selflimit
inflamm
larg
airway
lung
bronchi
due
infect
oppos
pneumonia
lower
airway
involv
chest
imag
gener
normal
patient
typic
present
cough
last
day
import
factor
distinguish
mild
upper
respiratori
infect
uri
symptom
usual
persist
day
may
extend
week
patient
report
purul
sputum
indic
slough
tracheobronchi
epithelium
inflamm
oppos
bronchiol
acut
bronchiti
usual
present
progress
cough
wheez
tachypnea
respiratori
distress
hypoxemia
chronic
bronchiti
hand
entail
continu
symptom
day
month
least
month
year
two
consecut
year
mani
studi
shown
communityacquir
virus
far
common
caus
acut
bronchiti
includ
influenza
b
adenoviru
rhinoviru
coronaviru
parainfluenza
rsv
human
metapneumoviru
bacteria
particularli
atyp
organ
also
caus
acut
bronchiti
commonli
implic
pathogen
includ
bordetella
pertussi
chlamydophila
pneumonia
mycoplasma
pneumonia
among
immunocompromis
patient
caus
agent
acut
bronchiti
larg
similar
gener
popul
opportunist
pathogen
also
caus
tracheobronchi
infect
particularli
among
lung
transplant
allogen
hsct
recipi
import
includ
invas
fungal
infect
especi
aspergillu
acut
bronchiti
affect
adult
annual
major
infect
occur
fall
winter
incid
upper
respiratori
tract
infect
among
solid
organ
transplant
hsct
recipi
appear
similar
gener
popul
despit
similar
epidemiolog
immunocompromis
patient
often
suffer
prolong
period
viral
shed
progress
pneumonia
frequent
higher
rate
airflow
obstruct
increas
mortal
also
key
differ
respiratori
viral
infect
immedi
prior
bone
marrow
transplant
associ
decreas
surviv
among
lung
transplant
recipi
respiratori
viral
infect
particularli
rsv
associ
progress
chronic
reject
bronchiol
obliteran
syndrom
bo
histopatholog
examin
patient
undergo
allogen
hematopiet
stem
cell
transplant
similarli
risk
bo
potenti
may
trigger
episod
respiratori
viral
infect
major
procedur
employ
diagnosi
upper
respiratori
tract
infect
includ
multiplex
pcr
platform
sputum
cultur
fungal
etiolog
suspect
bronchoscopi
often
perform
establish
microbiolog
diagnosi
among
lung
transplant
recipi
examin
bronchial
anastomosi
essenti
ascertain
integr
presenc
necrosi
treatment
acut
bronchiti
depend
caus
infecti
agent
viral
organ
without
establish
therapi
support
care
close
monitor
recommend
pleas
refer
specif
pathogen
inform
treatment
cap
defin
idsa
at
refer
radiograph
clinic
develop
pneumonia
commun
set
distinguish
hap
outlin
distinct
cap
nosocomi
pneumonia
remain
import
allow
predict
like
pathogen
permit
prognost
estim
base
epidemiolog
descript
underli
caus
consequ
distinct
provid
framework
decis
regard
appropri
diagnost
evalu
empir
antimicrobi
therapi
etiolog
spectrum
bacteri
pathogen
caus
cap
among
transplant
recipi
mildtomoder
immunosuppress
similar
patient
without
histori
transplant
howev
clinic
insignific
microbi
inoculum
gener
popul
may
caus
sever
infect
among
patient
underli
immunosuppress
pneumonia
remain
commonli
identifi
pathogen
frequent
caus
lethal
cap
aureu
nontyp
haemophilu
influenza
pseudomona
spp
gnb
may
also
caus
lifethreaten
cap
recent
nonlactos
ferment
nf
gnb
stenotrophomona
burkholderia
chryseobacterium
achromobact
alcaligen
speci
increasingli
recogn
etiolog
agent
cap
nosocomi
infect
pyogen
neisseria
meningitidi
moraxella
catarrhali
also
caus
cap
less
frequent
incid
cap
associ
atyp
pathogen
mycoplasma
pneumonia
chlamydia
pneumonia
legionella
spp
vari
wide
patient
age
season
variat
geograph
locat
viral
pneumonia
commonli
caus
influenza
parainfluenza
adenoviru
also
sourc
cap
may
sever
set
transplant
import
note
lower
respiratori
tract
infect
may
due
mix
popul
virus
bacteria
fungi
solid
organ
transplant
hsct
recipi
microbiolog
diagnosi
cap
base
upon
recoveri
like
pathogen
otherwis
steril
sourc
like
blood
urin
pleural
fluid
isol
noncommens
organ
respiratori
secret
posit
result
select
serolog
test
although
util
gram
stain
cultur
expector
sputum
diagnosi
pneumonia
debat
year
care
procur
sputum
specimen
cytolog
confirm
lower
respiratori
sourc
appear
diagnost
use
particularli
obtain
initi
antimicrobi
therapi
time
establish
accur
diagnosi
contribut
success
outcom
although
treatment
withheld
diagnost
intervent
underway
antimicrobi
select
base
upon
probabl
infect
organ
sever
patient
pneumonia
patient
underli
immun
statu
presenc
absenc
comorbid
condit
lower
respiratori
tract
infect
occur
h
hospit
admiss
patient
without
anteced
clinic
symptom
radiograph
find
suggest
pneumonia
refer
hap
etiolog
spectrum
microbi
pathogen
caus
hap
among
lowrisk
transplant
recipi
recent
antibiot
exposur
similar
seen
gener
popul
h
influenza
pneumonia
aureu
enterobacteriacea
frequent
encount
methicillinresist
aureu
mrsa
may
caus
sever
hap
especi
among
patient
prior
mrsa
colon
antibiot
exposur
advanc
age
andor
prolong
ventilatori
support
protract
mechan
ventil
recent
antibiot
administr
also
associ
increas
rate
hap
caus
p
aeruginosa
acinetobact
baumannii
complex
enterobact
spp
emerg
strain
mdr
nfgnb
maltophilia
burkholderia
cepacia
complex
alcaligen
achromobact
speci
may
difficult
treat
mortal
rate
associ
hap
due
mrsa
p
aeruginosa
disproportion
higher
caus
nosocomi
bacteri
pathogen
polymicrobi
isol
mdr
pathogen
common
among
patient
hap
particularli
occur
late
complic
hospit
frequenc
multipl
organ
identifi
singl
respiratori
sampl
recent
evidencebas
guidelin
advoc
use
quantit
semiquantit
lower
respiratori
tract
cultur
obtain
either
bronchoscop
noninvas
part
initi
evalu
patient
suspect
hap
vap
empir
antibiot
select
hap
develop
within
day
admiss
target
pneumonia
aureu
includ
mrsa
streptococcu
spp
h
influenza
enterobacteriacea
patient
late
hap
occur
week
hospit
receiv
empir
antimicrobi
therapi
includ
coverag
mdrgnb
scope
altern
antimicrobi
choic
patient
refractori
slowtorespond
hap
vap
base
institutiondepend
suscept
profil
institut
incid
mrsa
pneumonia
low
respiratori
cultur
unavail
unrev
screen
mrsa
nasal
colon
may
use
guid
therapi
absenc
mrsa
nasal
colon
high
neg
predict
valu
mrsa
pneumonia
coverag
organ
often
discontinu
earli
treatment
cours
screen
swab
neg
aspir
orogastr
content
mechan
obstruct
airway
may
creat
favor
milieu
pneumonia
caus
microaerophil
anaerob
bacteria
like
peptostreptococcu
spp
varieti
factor
abnorm
swallow
function
alter
cough
reflex
impair
mucociliari
clearanc
alter
mental
statu
use
sedat
medic
chemotherapyinduc
mucos
supin
posit
gastroparesi
mechan
ventil
nasogastr
tube
feed
contribut
increas
predilect
aspir
patient
histori
transplant
malign
pneumonia
associ
largevolum
aspir
gastric
content
typic
occur
late
find
acid
gastric
content
act
poor
medium
bacteri
growth
thu
initi
clinic
syndrom
follow
aspir
gastric
content
aris
direct
caustic
effect
acid
aspir
cell
alveolarcapillari
interfac
ie
chemic
pneumon
true
bacteri
pneumonia
occur
consequ
superimpos
process
aspir
oral
content
contrast
result
inhal
nonsteril
oropharyng
materi
clinic
present
often
insidi
diagnosi
commonli
infer
base
compat
patient
risk
profil
coupl
radiograph
evid
pneumonia
chest
radiograph
may
show
focal
abnorm
correl
patient
posit
time
aspir
exampl
aspir
occur
patient
upright
posit
typic
local
basilar
segment
lower
lobe
wherea
superior
segment
lower
lobe
posterior
segment
upper
lobe
frequent
affect
follow
aspir
occur
supin
posit
major
pathogen
underli
nosocomi
versu
communityacquir
aspir
pneumonia
differ
although
microbiolog
diagnosi
may
establish
due
limit
yield
convent
anaerob
cultur
necessari
cultur
may
best
obtain
bronchoscop
use
protect
strategi
manag
patient
signific
lung
injuri
associ
aspir
gastric
content
includ
aggress
support
care
upper
airway
suction
pulmonari
toilet
necessari
posit
pressur
ventil
compris
mainstay
therapi
clearli
establish
role
corticosteroid
set
though
practic
prescrib
moder
highdos
prednisolon
uncommon
earli
aggress
antimicrobi
therapi
recommend
patient
pneumonia
secondari
aspir
oropharyng
content
antimicrobi
select
tailor
immun
statu
patient
set
aspir
occur
ie
commun
vs
healthcar
environ
gener
broad
spectrum
target
gramneg
organ
oral
anaerob
anaerob
coverag
may
particularli
import
patient
periodont
diseas
putrid
sputum
evid
necrot
pneumonia
transplant
recipi
alter
pulmonari
anatomi
specif
lung
transplant
recipi
bronchial
anastomot
strictur
may
risk
obstruct
airway
atelectasi
postobstruct
pneumonia
associ
pneumonia
tend
polymicrobi
natur
includ
gnb
staphylococci
anaerob
may
requir
relief
obstruct
achiev
adequ
antimicrobi
effect
even
appropri
antibiot
select
often
rapidli
achiev
intervent
bronchoscop
techniqu
bronchial
dilat
without
stent
placement
lung
may
also
becom
infect
via
septic
emboli
aris
suppur
endovascular
bacteri
less
commonli
fungal
infect
infect
intravascular
septic
deep
venou
thrombi
increasingli
recogn
potenti
sourc
infect
immunosuppress
patient
radiograph
pattern
patient
distinct
includ
multicentr
pleomorph
lung
nodul
asymmetr
rel
small
thickwal
caviti
speci
associ
human
diseas
nocardia
asteroid
complex
includ
n
asteroid
sensu
stricto
n
farcinica
account
nearli
nocardia
infect
cancer
patient
gener
popul
risk
factor
pneumonia
includ
profound
defici
cellular
immun
prolong
use
highdos
system
corticosteroid
especi
treatment
chronic
lung
diseas
presenc
gvhd
solid
organ
transplant
recipi
also
particular
risk
nocardia
infect
although
vari
base
upon
organ
transplant
one
review
demonstr
infect
rate
among
recipi
lung
heart
intestin
liver
kidney
respect
nocardia
infect
commonli
occur
within
year
transplant
although
earli
month
late
year
infect
also
report
infect
organ
consid
nodular
pulmonari
infiltr
seen
although
reticulonodular
diffus
infiltr
occasion
describ
solitari
nodul
associ
irregular
thickwal
caviti
mimic
invas
pulmonari
aspergillosi
histoplasmosi
necrot
cancer
chronic
bacteri
lung
abscess
also
associ
nocardia
infect
indol
pneumonia
may
clinic
indistinguish
actinomycet
infect
pneumonia
caus
pulmonari
eumycet
sever
immunosuppress
cancer
patient
refractori
leukemia
prior
allogen
hsct
may
present
rapidli
progress
multifoc
nocardiosi
spontan
pneumothorax
hemoptysi
also
recogn
present
nocardia
infect
among
immunocompromis
patient
concomit
brain
involv
uncommon
preemptiv
evalu
recommend
diagnos
asymptomat
brain
abscess
patient
pulmonari
nocardia
infect
trimethoprimsulfamethoxazol
mgkg
daili
effect
mani
nocardia
speci
retrospect
studi
suggest
clinic
outcom
improv
appropri
therapi
given
extend
period
time
month
despit
aggress
antimicrobi
therapi
pulmonari
nocardiosi
carri
high
mortal
immunosuppress
individu
pulmonari
actinomycosi
typic
present
similar
manner
nocardiosi
although
classic
associ
invas
across
tissu
plan
pulmonari
infect
may
involv
adjoin
pleura
subsequ
erod
chest
wall
isol
actinomycet
respiratori
tract
evalu
critic
presenc
may
repres
oropharyng
contamin
mycobacterium
rare
caus
pulmonari
infect
develop
world
import
consid
sever
immunosuppress
patient
especi
foreignborn
individu
patient
undergo
allograft
solid
organ
stem
cell
translant
develop
countri
tuberculosi
regard
endem
diseas
solid
organ
transplant
recipi
estim
time
higher
incid
activ
tuberculosi
gener
popul
frequenc
diseas
vari
base
upon
organ
transplant
time
transplant
twothird
case
occur
within
year
transplant
broad
rang
clinic
manifest
may
possibl
tuberculosi
infect
pulmonari
tuberculosi
may
present
insidi
pneumonia
difficult
distinguish
actinomycet
eumycet
infect
patient
impair
tcell
respons
may
develop
rapidli
progress
tuberculosi
follow
cours
virul
bacteri
infect
system
corticosteroid
therapi
independ
predictor
tuberculosi
reactiv
suboptim
respons
combin
antimicrobi
therapi
henc
diagnosi
tuberculosi
establish
everi
effort
made
discontinu
steroid
therapi
indic
specif
syndrom
hivinfect
patient
may
develop
clinic
worsen
tuberculosi
pneumonia
initi
antiretrovir
therapi
immun
reconstitut
inflammatori
syndrom
tuberculosisrel
lung
diseas
solid
organ
transplant
hsct
recipi
may
infrequ
worsen
immun
function
recov
follow
temporari
discontinu
partial
withdraw
antireject
antigvhd
therapi
nonetheless
minim
immunosuppress
may
help
clear
infect
nontubercul
mycobacteria
ntm
ubiquit
environ
gener
caus
infect
host
specif
anatom
immunolog
defect
transplant
recipi
particular
risk
due
impair
cellmedi
immun
among
patient
structur
lung
diseas
particularli
lung
transplant
risk
compound
anatom
abnorm
epidemiolog
data
somewhat
lack
pathogen
ntm
infect
report
infect
incid
rate
ntm
pulmonari
infect
estim
among
heart
transplant
recipi
among
lung
transplant
recipi
pulmonari
ntm
infect
classic
caus
aviumintracellular
complex
slowgrow
mycobacteria
opportunist
pathogen
frequent
associ
chronic
indol
pneumonia
unit
state
rapidli
grow
mycobacteria
particularli
abscessu
fortuitum
emerg
anoth
import
albeit
less
frequent
caus
ntm
lung
diseas
diagnosi
pulmonari
ntm
infect
remain
challeng
identif
organ
respiratori
cultur
may
result
colon
respiratori
tract
environment
contamin
causal
suggest
identif
ntm
steril
lower
respiratori
tract
specimen
coupl
correspond
clinic
manifest
chronic
nonproduct
cough
exert
dyspnea
ntm
lung
diseas
compat
radiograph
present
fever
night
sweat
weight
loss
pleurit
chest
pain
pleural
effus
also
possibl
less
frequent
absenc
system
dissemin
infect
radiograph
featur
ntm
infect
includ
upper
lobe
predomin
nonspecif
nodular
lesion
small
thinwal
caviti
chest
ct
find
demonstr
characterist
treeinbud
appear
may
also
seen
patient
chronic
infect
socal
ladi
windermer
syndrom
character
relaps
refractori
pulmonari
ntm
infect
due
slowgrow
mycobacteria
may
seen
patient
defect
endogen
interferongamma
cellular
immun
respons
ntm
pulmonari
infect
usual
insidi
although
rapidli
progress
diseas
seen
patient
profound
defect
helper
tcell
treatment
includ
least
two
antimicrobi
agent
mycobacterium
suscept
similar
ntm
p
jirovecii
previous
known
p
carinii
thought
ubiquit
environ
caus
infect
set
impair
immun
classic
describ
hivposit
individu
pronounc
lymphocytopenia
pneumocysti
import
pathogen
solid
organ
transplant
recipi
immunosuppress
patient
pneumocysti
pneumonia
present
slowli
progress
infect
accompani
nonproduct
cough
exert
dyspnea
hypoxemia
although
acut
rapidli
progress
form
describ
ct
evid
perihilar
infiltr
may
mistaken
pneumon
caus
common
acquir
viral
infect
rsv
influenza
parainfluenza
cmv
earli
phase
infect
bronchoalveolar
lavag
typic
high
diagnost
yield
either
silver
stain
pcr
amplif
highdos
trimethoprimsulfamethoxazol
mgkg
daili
given
day
treatment
choic
adjuv
system
corticosteroid
administ
patient
sever
hypoxemia
oral
atovaquon
primaquin
plu
clindamycin
parenter
pentamidin
may
given
patient
intoler
sulfacontain
regimen
invas
pulmonari
aspergillosi
ipa
rel
common
caus
pneumonia
patient
undergo
allogen
hsct
sever
immunosuppress
patient
follow
highrisk
solid
organ
allograft
transplant
among
cancer
patient
risk
factor
invas
pulmonari
aspergillosi
includ
prolong
week
sever
neutropenia
refractori
leukemia
allogen
hsct
gvhd
immunosuppress
therapi
treatment
highdos
system
corticosteroid
among
solid
organ
transplant
recipi
risk
factor
vari
base
upon
organ
transplant
often
includ
renal
failur
reoperationretransplant
cmv
infect
commonli
encount
although
nonfumigatu
aspergillu
speci
increasingli
recogn
similarli
mark
increas
pulmonari
invas
fungal
infect
due
nonaspergillu
mold
includ
fusarium
pseudallescheria
boydii
scedosporium
spp
dematiac
black
mold
also
note
make
select
effect
empir
regimen
challeng
increas
incid
pulmonari
mucormycosi
may
relat
chang
antifung
util
shift
away
amphotericin
b
compound
favor
moldact
triazol
drug
like
voriconazol
effect
newer
triazol
agent
like
posaconazol
isavuconazonium
overal
feasibl
efficaci
safeti
magag
fungal
pneumonia
transplant
recipi
evolv
appear
encourag
clinic
symptom
fungal
pneumonia
may
similar
seen
bacteri
pneumonia
ct
imag
may
reveal
highli
suggest
halo
sign
earli
cours
infect
andor
less
often
observ
crescent
sign
becom
appar
later
cours
ipa
despit
case
pulmonari
mycosi
radiograph
find
time
present
peripher
pleuralbas
lung
nodul
sometim
thickwal
regular
irregular
caviti
definit
diagnosi
pulmonari
invas
fungal
infect
requir
demonstr
fungal
hypha
within
involv
lung
tissu
therefor
clinic
diagnosi
often
made
infer
high
preval
thrombocytopenia
coagulopathi
transplant
recipi
render
lung
biopsi
unsaf
import
note
isol
fungi
respiratori
sampl
may
misrepres
etiolog
underli
pulmonari
infiltr
may
reflect
environment
contamin
respiratori
tract
colon
measur
fungal
antigen
serum
galactomannan
bronchoalveolar
lavag
galactomannan
serum
betadglucan
aid
detect
invas
pulmonari
mycosi
newer
assay
includ
sequencebas
nucleic
acid
amplif
techniqu
may
alter
diagnost
strategi
use
invas
fungal
infect
futur
therapeut
strategi
infect
discuss
elsewher
previous
note
respiratori
virus
includ
rsv
influenza
b
parainfluenza
adenoviru
common
caus
upper
respiratori
tract
infect
may
lower
respiratori
tract
manifest
immunosuppress
patient
human
metapneumoviru
hmpv
also
recogn
seriou
pulmonari
pathogen
popul
spectrum
hmpv
diseas
may
rang
mild
upper
respiratori
tract
infect
seriou
dissemin
infect
lead
respiratori
failur
enceph
herpesvirus
particularli
cmv
also
import
caus
pneumon
transplant
recipi
invas
cmv
diseas
often
affect
transplant
allograft
lung
transplant
recipi
particularli
high
risk
cmv
pneumon
viru
immunomodulatori
natur
cmv
associ
bacteri
fungal
superinfect
well
lymphoprolif
disord
fever
nonproduct
cough
promin
nonspecif
featur
viral
respiratori
tract
infect
patient
extens
lung
involv
dyspnea
may
appear
earli
cours
infect
viral
nucleic
acid
nasal
wash
tracheal
aspir
bronchial
specimen
frequent
use
diagnos
viral
respiratori
infect
multiplex
pcr
platform
despit
isol
cmv
especi
pcr
amplif
lower
respiratori
tract
secret
may
necessarili
indic
cmv
lung
infect
even
transplant
recipi
sever
cellular
immun
defect
intermitt
lowlevel
viral
replic
shed
viru
without
develop
viral
lung
diseas
well
establish
host
risk
assess
cmv
diseas
suscept
evalu
along
radiograph
imag
nonivcontrast
chest
ct
scan
prove
help
discern
activ
viral
lung
diseas
versu
nondiseas
associ
cmv
respiratori
tract
viral
shed
note
chest
ct
scan
may
show
ground
glass
opac
even
convent
chest
radiograph
unremark
improv
sensit
diagnosi
ganciclovir
foscarnet
commonli
prescrib
system
cmv
infect
transplant
recipi
cmv
pneumon
ivig
immun
modul
along
effect
antivir
drug
recommend
detail
discuss
provid
regard
specif
pathogen
approach
toward
therapeut
manag
lung
infect
chapter
throughout
book
